"First do no harm" and the importance of prediction in oncology

EPMA Journal

Volumn 1, Issue 3, 2010, Pages 369-375

  Characiejus, Dainius ^a,b   Hodzic, Jasmina ^c   Jacobs, John J L ^c  

^a VILNIUS UNIVERSITY   (Lithuania)

^b Center for Innovative Medicine   (Lithuania)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer promoting effects; Chemotherapy; Immunotherapy; Radiotherapy; Surgery

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ANTIINFECTIVE AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER VACCINE; CANVAXIN; CISPLATIN; CYTOCHROME P450; DOCETAXEL; EPIPODOPHYLLOTOXIN; GAMMA INTERFERON; GANGLIOSIDE VACCINE; INTERLEUKIN 2; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BLADDER CANCER; BONE CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOTOXICITY; CHILDHOOD LEUKEMIA; DNA DAMAGE; DRUG CARCINOGENICITY; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; ONCOLOGY; OUTCOME ASSESSMENT; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION CARCINOGENESIS; RADIATION INDUCED NEOPLASM; REVIEW; RISK BENEFIT ANALYSIS; SOFT TISSUE SARCOMA; SURVIVAL TIME; TESTIS CANCER; TUMOR GROWTH;

EID: 79953060959     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0042-1     Document Type: Review

References (60)

1. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005; 365: 176-86.
2. Ganz PA. The price of anticancer intervention. Treatment-induced malignancy. Lancet Oncol. 2002; 3: 575-6.
3. Ganz PA. Harnessing personalised medicine to prevent late effects. Lancet Oncol. 2010; 11: 7-9.
4. Lundy J. Anesthesia and surgery: a double-edged sword for the cancer patient. J Surg Oncol. 1980; 14: 61-5.
5. Lee JW, Shahzad MM, Lin YG, et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009; 15: 2695-702.
6. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep. 1976; 60: 1749-60.
7. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979; 39: 3861-5.
8. Nomi S, Naito K, Kahan BD, Pellis NR. Effects of concomitant and sinecomitant immunity on postsurgical metastasis in mice. Cancer Res. 1986; 46: 6111-5.
9. Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989; 49: 1996-2001.
10. Carter JJ, Feingold DL, Oh A, et al. Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice. Surg Innov. 2006; 13: 41-7.
11. Characiejus D, Dullens HF, Den Otter W. Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system. Cancer Immunol Immunother. 1990; 32: 179-84.
12. Retsky M, Bonadonna G, Demicheli R, et al. Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res. 2004; 6: R372-4.
13. Baum M, Demicheli R, Hrushesky W, Retsky M. Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. 2005; 41: 508-15.
14. Hogle WP. The state of the art in radiation therapy. Semin Oncol Nurs. 2006; 22: 212-20.
15. Marees T, van Leeuwen FE, de Boer MR, et al. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer. 2009; 45: 3245-53.
16. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003; 21: 3431-9.
17. Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40, 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005; 97: 1354-65.
18. Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008; 180: 2005-9.
19. Hoskin P. The price of anticancer intervention. Secondary malignancies after radiotherapy. Lancet Oncol. 2002; 3: 577-8.
20. von Essen CF. Radiation enhancement of metastasis: a review. Clin Exp Metastasis. 1991; 9: 77-104.
21. Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001; 61: 2207-11.
22. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009; 27: 328-33.
23. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009; 23: 1625-37.
24. Lowenthal RM, Eaton K. Toxicity of chemotherapy. Hematol/Oncol Clin North Am. 1996; 10: 967-90.
25. Kaufman D, Longo DL. Hodgkin's disease. Crit Rev Oncol Hematol. 1992; 13: 135-87.
26. Carmo-Pereira J, Costa FO, Henriques E, et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer. 1987; 56: 471-3.
27. West H, Lilenbaum R, Harpole D, et al. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol. 2009; 4: S1029-39.
28. Eguchi H, Ishikawa O, Ohigashi H, et al. Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas. 2009; 38: 791-8.
29. Derenzini M, Brighenti E, Donati G, et al. The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein. J Pathol. 2009; 219: 373-82.
30. Godai TI, Suda T, Sugano N, et al. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer. 2009; 9: 420.
31. Stewart DA, Bahlis N, Mansoor A. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma. 2009; 50: 1276-82.
32. van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008; 11: 77-98.
33. Bijl MJ, van Schaik RH, Lammers LA, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat. 2009; 118: 125-30.
34. Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs. 2008; 12: 627-38.
35. Lehrnbecher T, Koehl U, Wittekindt B, et al. Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncol. 2008; 9: 269-78.
36. Geldof AA, Rao BR. Doxorubicin treatment increases metastasis of prostate tumor (R3327-MatLyLu). Anticancer Res. 1988; 8: 1335-9.
37. De Larco JE, Wuertz BR, Manivel JC, et al. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res. 2001; 61: 2857-61.
38. Böhle A. Bladder cancer: meta-analysis of BCG versus mitomycin C-a deeper insight? Nat Rev Urol. 2010; 7: 8-10.
39. Den Otter W, Jacobs JJ, Battermann JJ, et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother. 2008; 57: 931-50.
40. Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther. 2008; 8: 1495-505.
41. McDermott DF, Atkins MB. Immunotherapy of metastatic renal cell carcinoma. Cancer J. 2008; 14: 320-4.
42. Prehn RT. An immune reaction may be necessary for cancer development. Theor Biol Med Model. 2006; 3: 6.
43. Kelly SA, Gschmeissner S, East N, et al. Enhancement of metastatic potential by gamma-interferon. Cancer Res. 1991; 51: 4020-7.
44. Lollini PL, Bosco MC, Cavallo F, et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer. 1993; 55: 320-9.
45. Siegel CT, Schreiber K, Meredith SC, et al. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med. 2000; 191: 1945-56.
46. Chiarella P, Reffo V, Bruzzo J, et al. Therapeutic anti-tumor vaccines: from tumor inhibition to enhancement. Clin Med Oncol. 2008; 2: 237-45.
47. Fifis T, Lam I, Lin D, et al. Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases. Vaccine. 2008; 26: 241-9.
48. Meyskens Jr FL, Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst. 1995; 87: 1710-3.
49. Wiesenfeld M, O'Connell MJ, Wieand HS, et al. Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol. 1995; 13: 2324-9.
50. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994; 12: 2321-6.
51. Characiejus D, Pasukoniene V, Kazlauskaite N, et al. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res. 2002; 22: 3679-83.
52. Focosi D, Bestagno M, Burrone O, et al. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol. 2010; 87: 107-16.
53. Janku F, Kurzrock R. Adjuvant interferon in high-risk melanoma: end of the era? J Clin Oncol. 2010; 28: e15-6.
54. Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010; 102: 493-501.
55. Cartei G, Sala PG, Sanzari M, et al. Reduced lymphocyte subpopulations in patients with advanced or disseminated melanoma. J Am Acad Dermatol. 1993; 28: 738-44.
56. Elliott GT, McLeod RA, Perez J, Von Eschen KB. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol. 1993; 9: 264-72.
57. Batliwalla FM, Bateman BA, Serrano D, et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med. 1998; 4: 783-94.
58. Characiejus D, Pasukoniene V, Jonusauskaite R, et al. Peripheral blood CD8highCD57+ lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-alpha. Anticancer Res. 2008; 28: 1139-42.
59. Eggermont AM. Therapeutic vaccines in solid tumours: can they be harmful? Eur J Cancer. 2009; 45: 2087-90.
60. Jacobs JJL, Characiejus D, Scheper RJ, et al. The Amiens strategy: small phase III trials for clinically relevant progress in the war against cancer. J Clin Oncol. 2009; 27: 3062-3.